Issue

FDA’s Proposed 503B Exclusion for GLP-1 Compounds: What It Means for Patients2026-06-12FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Here is what that could mean for compounded GLP-1 medicines, safety checks, and patient questions.